Krka UK has announced the launch of Arocenia 10mg/ml injectable solution, a new addition to its expanding portfolio of generic pharmaceuticals. Containing the active ingredient maropitant, a neurokinin-1 (NK1) receptor antagonist, Arocenia is licensed for the prevention and treatment of vomiting in dogs and cats, including peri-operative use and chemotherapy-associated indications in dogs.
Unveiled at BVA Live 2025, Arocenia provides fast, broad-spectrum anti-emetic efficacy with a 24-hour duration of action following a single daily dose. It can be administered intravenously or subcutaneously and is supplied in 20ml multi-dose vials, allowing up to 40 punctures per vial and a 60-day open vial shelf life.
Renzo Di Florio, Krka’s technical veterinary adviser, commented “Vomiting is one of the most common presenting signs in small animal practice, and maropitant is a medication you’ll find on just about every vet’s dispensary shelf. With Arocenia, we’re adding a cost-effective formulation to the available options.”
Arocenia supports a wide range of clinical applications, including the prevention of peri-operative nausea and vomiting and improving recovery from general anaesthesia after the use of the u-receptor agonist, morphine. It also provides important antiemetic support during chemotherapy and is indicated for prevention of nausea and vomiting in cats across varied clinical contexts. Its broad indication range make it a useful option for busy small animal clinics.
Will Ridgway, head of animal health at Krka UK, added “With so many pressures on practice workflow, having products that are accessible, cost-effective and reliable is essential. Arocenia reflects that approach - and because we manage our own manufacturing in Europe, we can offer the consistency and supply reassurance that veterinary teams rely on.”
More information on the drug can be found here, alternatively contact KRKA UK here.
Author
